


ATTORNEY DOCKET NO. 9250.22

PATENT

Receipt  
# 14 1/2  
9-20-01  
12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Goudsmit, et al.  
Serial No.: 09/463,352 Group Art Unit: 1655  
Filed: January 21, 2000  
For: NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND  
PROBES IN THE AMPLIFICATION AND DETECTION OF ALL  
SUBTYPES OF HIV-1



June 18, 2001

Commissioner for Patents  
Washington, DC 20231

RECEIVED

SEP 20 2001

TECH CENTER 1600/2900


REQUEST FOR CORRECTED FILING RECEIPT

Sir:

In reviewing the Filing Receipt (copy attached) for the above referenced application, Applicant notes that the invention title appears incorrectly as NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS PROBES IN AMPLIFICATION AND DETECTION OF ALL SUBTYES OF HIV-1. The invention title should read NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN THE AMPLIFICATION AND DETECTION OF ALL SUBTYPES OF HIV-1.

Applicant further respectfully requests that a corrected filing receipt be issued.


Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31,665

USPTO Customer No. 20792  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, North Carolina 27627  
Telephone (919) 854-1400  
Facsimile (919) 854-1401

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on June 18, 2001.



Vickie Diane Prior

Date of Signature: June 18, 2001


## FILING RECEIPT



\*OC00000005008321\*

UNITED STATES DEPARTMENT OF  
COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/463,352	01/21/2000	1646	840	T/97300 US			1

WILLIAM M BLACKSTONE  
AKZO NOBEL  
1300 PICCARD DRIVE  
SUITE #206  
ROCKVILLE, MD 20850-4373

Date Mailed: 03/24/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

JAAP GOUDSMIT, AMSTERDAM, NETHERLANDS;  
PIETER OUDSHOORN, ST. MICHIELSGESTEL, NETHERLANDS;  
SUZANNE JURRIAANS, MONNICKENDAM, NETHERLANDS;  
VLADIMIR VLADIMIROVICH LUKASHOV, DIEMEU, NETHERLANDS;

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/EP98/04945 08/05/1998

## Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 97202455.8 08/08/1997


If Required, Foreign Filing License Granted 03/24/2000

## Title

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS PROBES IN  
AMPLIFICATION DETECTION OF ALL SUBTYPES OF HIV-1

## Preliminary Class

435



Data entry by : BARRETO, NGA

Team : OIPE

Date: 03/24/2000

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**RECEIVED**  
SEP 20 2001  
TECH CENTER 1600/2900

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

